



Pharmacy Formulary Updates for April 2021

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status April 2021:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO - MA
Cometriq	\$3.65;PA;SP
Palynziq	\$3.65;PA;SP
ElELYso	MB/RX;PA;SP
Riabni	MB;PA
Zokinvy	\$3.65;PA
Orgovyx	\$3.65;PA
Imcivree	\$3.65;PA
Plegridy	NC;SP
Lifems	NC
Wynzora	NC
Pradaxa	\$3.65;QL;BP

Key

BP: Brand Preferred

MB: Medical Benefit

NC: Not covered

NTM: New-to-market

PA: Prior Authorization

QL: Quantity Limitation

SP: Specialty Pharmacy - provided through CVS/specialty

ST: Step Therapy

MB/RX: Drug can be dispensed through Medical Benefit or Prescription Benefit